Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Maintains $500 Price Target
Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Maintains $500 Price Target
奧本海默維持Vertex Pharmicals的跑贏大盤,維持500美元的目標股價
Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and maintains $500 price target.
奧本海默分析師哈塔傑·辛格維持Vertex Pharmicals(納斯達克股票代碼:VRTX)的跑贏大盤,並維持500美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。